ADVANCED FALLOPIAN TUBE CARCINOMA
Clinical trials for ADVANCED FALLOPIAN TUBE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED FALLOPIAN TUBE CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED FALLOPIAN TUBE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Zapping tumors: wearable device tested with drugs for tough cancers
Disease control Recruiting nowThis early-stage trial is testing the safety of combining a wearable device that uses electric fields to disrupt cancer cells with different drug combinations. It is for adults with advanced cancers in the abdomen or chest that have spread and who have run out of standard treatme…
Matched conditions: ADVANCED FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Cancer care comes home: mayo clinic tests house calls for treatment
Disease control Recruiting nowThis study is testing whether giving standard cancer treatments at home is as safe and effective as giving them in a clinic. It aims to see if receiving care at home reduces stress, improves quality of life, and is preferred by patients with advanced cancers. About 220 participan…
Matched conditions: ADVANCED FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Personalized vaccine trial aims to train immune system to fight advanced ovarian cancer
Disease control Recruiting nowThis study is testing whether a personalized vaccine made from a patient's own immune cells can help prevent or delay the return of advanced ovarian, fallopian tube, or primary peritoneal cancer. The vaccine is designed to teach the immune system to recognize and attack cancer ce…
Matched conditions: ADVANCED FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC